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Abstract
Histone deacetylase inhibitors (HDACIs) represent a class of promising agents that can improve 
radiotherapy in cancer treatment. However, the full therapeutic potential of HDACIs as 
radiosensitizers has been restricted by limited efficacy in solid malignancies. In this study, we 
report the development of nanoparticle (NP) formulations of HDACIs that overcome these 
limitations, illustrating their utility to improve the therapeutic ratio of the clinically established 
first generation HDACI vorinostat and a novel second generation HDACI quisinostat. We 
demonstrate that NP HDACIs are potent radiosensitizers in vitro and are more effective as 
radiosensitizers than small molecule HDACIs in vivo using mouse xenograft models of colorectal 
and prostate carcinomas. We found that NP HDACIs enhance the response of tumor cells to 
radiation through the prolongation of γ-H2AX foci. Our work illustrates an effective method for 
improving cancer radiotherapy treatment.
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Histone deacetylases (HDACs) are enzymes involved in the regulation of gene expression 
and chromatin modification [1]. Aberrant activity of HDACs has been implicated in cancer 
development. Consequently, the inhibition of HDACs has emerged as a promising strategy 
to reverse aberrant epigenetic states associated with cancer [2]. There has been extensive 
development of histone deacetylase inhibitors (HDACIs) as a new class of therapeutics for 
both solid tumors and hematologic malignancies. Unfortunately, these efforts have only 
resulted in approval of HDACIs (vorinostat (suberoylanilide hydroxamic acid, SAHA) and 
romidepsin (depsipeptide)) for the treatment of cutaneous T-cell lymphoma [3, 4]. In the 
clinic, HDACIs have not significantly improved outcomes in solid malignancies compared 
with current standard therapies [2]. One of the potential clinical applications of HDACIs is 
to improve radiotherapy treatment, a treatment that more than 60% of all cancer patients will 
receive [5]. Preclinical studies have indicated that a number of HDAC inhibitors are 
effective radiosensitizers [6], agents that sensitize tumor cells to radiotherapy, in a variety of 
solid malignancies such as colorectal cancer [7] and prostate cancer cells [8]. However, the 
radiosensitization effects have been associated with only mild improvements in efficacy. 
Given the promise of HDACIs as radiosensitizers, the identification of strategies to improve 
their therapeutic ratio is needed.
The specific mechanisms by which HDACIs induce radiosensitization remains unresolved, 
but may be due in part to the prevention of the DNA double strand (DBS) repair, the 
principal mechanism of action of radiotherapy, leading to subsequent tumor cell death [6, 9]. 
HDACIs have been shown to prolong the formation of phosphorylated histone H2AX 
(γH2AX), a marker of DSBs, following radiation [9-11]. HDACIs may promote the 
stabilization of DNA DSBs through a variety of mechanisms including the downregulation 
of specific DNA repair molecules such as Ku70, Ku86, Rad50 and Rad51 [6, 12]. HDAC 
inhibition may also lead to hyperacetylation of histones, leading to a more relaxed chromatin 
state [1]. This may enhance exposure of DNA to radiation-induced damage.
It has been postulated that the efficacy of established first-regeneration HDACIs were 
limited in solid tumor indications due to their suboptimal potency for specific HDAC 
enzymes and transient induction of histone acetylation in tumor tissue [13]. In agreement 
with this notion, it has been shown that prolonged exposure of HDACI vorinostat is 
necessary for tumor growth inhibition. Furthermore, vorinostat’s inhibitory activity is 
rapidly reversible upon removal of the drug [14]. This may explain the limited efficacy of 
vorinostat in combination with radiotherapy in solid malignancies. Thus, more potent 
second-generation HDACIs, such as quisinostat (JNJ-26481585) have been developed with 
the goal to prolong pharmacodynamic response and to increase efficacy [13]. Quisinostat 
have been shown to exert antiproliferative activity against a wide panel of cancer cell lines 
at nanomolar concentrations. The potent and prolonged activity of quisinostat is found to 
translate into higher in vivo potency in preclinical colorectal cancer tumor models than 
vorinostat. However, more potent HDACIs can also be associated with increased toxicity to 
normal tissues [15].
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Therefore, there are two key limitations in the current use of HDACIs as radiosensitizers. 
First, clinically established HDACIs may be inefficient at sustaining inhibition of DSB 
repair, leading to limited efficacy in improving radiotherapy. Second, more potent HDACIs 
may sensitize both tumor and normal cells to the effects of radiotherapy, leading to 
increased toxicity. Thus, there is strong interest in the development of novel strategies to 
further improve their therapeutic ratio in chemoradiotherapy. One approach is to utilize 
nanoparticle (NP) drug delivery vehicles. NPs preferentially accumulate in tumors and have 
low distribution in normal tissue [16, 17]. They can also release HDACIs in a slow and 
controlled fashion to further increase synergy with radiotherapy (Fig. 1b). We hypothesized 
that NP formulations of HDACIs will lead to higher therapeutic ratio when combined with 
radiotherapy than small molecule HDACIs. In this study, we engineered biodegradable and 
biocompatible NP formulations of first generation HDACI vorinostat and second generation 
HDACI quisinostat. These NP HDACIs were evaluated as radiosensitizers in vitro using two 
prostate and three colorectal cancer cell lines. The in vitro data was further validated in vivo 
using mouse xenograft models of prostate and colorectal cancers.
MATERIALS AND METHODS
Materials
Vorinostat was purchased from Biotang Inc (Boston, MA, USA). Quisinostat was obtained 
from Active Biochem (Maplewood, NJ, USA). Poly (D,L-lactide-coglycolide) (PLGA) with 
a 85:15 monomer ratio, ester terminated, and viscosity of 0.55-0.75 dL/g was purchased 
from Durect Corporation (Pelham, AL, USA). PLGA with a 50:50 monomer ratio, ester 
terminated, and viscosity of 0.72–0.92 dl/g was purchased from Durect Corporation 
(Pelham, AL). Soybean lecithin consisting of 90-95% (w/w) phosphatidylcholine was 
obtained from MP Biomedicals (Solon, OH, USA). DSPE-PEG2000-COOH [1,2-distearoyl-
sn-glycero-3-phosphoethanolamine-N-carboxy (polyethylene glycol) 2000] was purchased 
from Avanti Polar Lipids (Alabaster, AL, USA).
Characterization of nanoparticle vorinostat and nanoparticle quisinostat
NP vorinostat and NP quisinostat size (diameter, nm) and surface charge (ζ-potential, mV) 
were characterized using a Zetasizer Nano Z dynamic light scattering detector (Malvern 
Instruments, Westborough, MA, USA). Transmission electron microscopy (TEM) images of 
NP vorinostat and NP quisinostat were obtained at the Microscopy Services Laboratory 
Core Facility at the UNC School of Medicine.
Synthesis and characterization of nanoparticle vorinostat and nanoparticle quisinostat
PLGA-lecithin-PEG core-shell NPs were synthesized from PLGA, soybean lecithin, and 
DSPE-PEG-COOH using a modified nanoprecipitation technique[18]. Vorinostat and 
quisinostat was dissolved at a dosage of 10% (w/w) of the polymer into the PLGA/
acetonitrile solution before nanoprecipitation. The NP solution was washed twice using an 
Amicon Ultra-4 centrifugal filter (Millipore, MA, USA) with a molecular weight cutoff of 
30 kDa and then resuspended in PBS to obtain the final concentration. NP vorinostat and NP 
quisinostat size (diameter, nm) and surface charge (ζ-potential, mV) were characterized 
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using a Zetasizer Nano Z dynamic light scattering detector (Malvern Instruments Ltd, 
Worcestershire, UK).
Nanoparticle vorinostat and nanoparticle quisinostat release
To measure the release profile of vorinostat from NP vorinostat and quisinostat from NP 
quisinostat, 400 μ L of NP vorinostat or NP quisinostat solution at a concentration of 1 
mg/mL was aliquot equally into Slide-A-Lyzer MINI dialysis microtubes with a molecular 
weight cut-off of 2 kDa (Pierce, Rockford, IL, USA) and subjected to dialysis against 4 L of 
phosphate-buffered saline (PBS) with gentle stirring at 37°C. PBS was changed periodically 
during the dialysis process. At the indicated times, 0.1 mL of solution from three microtubes 
was removed and mixed with an equal volume of acetonitrile to dissolve the NPs. Vorinostat 
and quisinostat content from their respective NPs were quantitatively analyzed using an 
Agilent 1100 HPLC (Palo Alto, CA, USA) equipped with a C18 chromolith flash column 
(Merck KGaA Darmstadt, Germany). Vorinostat absorbance was measured by a UV–VIS 
detector at 228 nm and in 0.25 mL/min gradient (from 0:100 to 100:0) of acetonitrile/water. 
Quisinostat absorbance was measured by a UV–VIS detector at 228 nm and in 0.25 mL/min 
gradient (from 0:100 to 100:0) of methanol: water with 0.1% TFA.
Cell culture
DU145, PC3, HCT116, and SW620 cells were acquired from the Tissue Culture Facility at 
the Lineberger Comprehensive Cancer Center at UNC. DU145 cells were cultured in 
EMEM supplemented with 10% fetal bovine serum (FBS) (Mediatech, Manassas, VA, 
USA), nonessential amino acids (Mediatech), and penicillin/streptomycin (Mediatech), and 
sodium pyruvate (Gibco). PC3 cells were cultured in DMEM/F12 (Gibco) supplemented 
with 10% FBS and penicillin/streptomycin (Mediatech). HCT116 cells was cultured in 
McCoy’s 5A with L-glutamine (Mediatech) supplemented with 10% FBS and penicillin/
streptomycin (Mediatech). SW620 cells was cultured in DMEM-H (Gibco, Invitrogen, 
Carlsbad, CA, USA) supplemented with 10% FBS (Mediatech) and penicillin/streptomycin 
(Mediatech). SW837 (ATCC™ CCL-235™) (ATCC, Manassas, VA, USA) cells were 
maintained in DMEM-H (Gibco, Invitrogen, Carlsbad, CA, USA) supplemented with 10% 
FBS (Mediatech) and penicillin/streptomycin (Mediatech).
Clonogenic survival assay
Cells were treated with 1 μM of vorinostat or 1 μM quisinostat either without NPs or 
encapsulated in NPs for 24 h. Cells were washed 2 times with phosphate buffer saline (PBS) 
after incubation. Cells were then seeded at various densities ranging from 100 to 50,000 
cells in 4 mL of culture medium in 50 mL flasks following treatment. The cells were then 
irradiated at 0, 2, 4, 6 or 8 Gy. Radiotherapy was given using a Precision X-RAD 320 
(Precision X-Ray, Inc., North Branford, CT) machine operating at 320 kvp and 12.5mA. The 
dose rate at a source-subject distance of 50 cm was 2.07 Gy/min. The cells were incubated 
for 10 days following irradiation. After 10 days, the cells were fixed in 1:1 acetone/methanol 
and were stained with trypan blue. Colonies with over 50 cells were counted. The relative 
survival fraction was calculated by dividing the number of colonies of irradiated cells by the 
number of cells plated, with correction for the plating efficiency. The average plating 
efficiency (%) for PC3, DU145, HCT116, SW620, and SW837 cells were 52, 40, 66, 66, 
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and 29 respectively. Survival fractions significantly lower than 0.001 were excluded from 
analysis.
Immunofluorescent Staining for γ-H2AX
1×105 PC3 cells were grown in a 24-well plate and treated with 1 μM small molecule 
vorinostat equivalent of NP vorinostat or vorinostat. Cells were incubated for 24 hr and then 
washed in PBS thrice and incubated with fresh medium. The cells were then treated with 2 
Gy using a Precision XRAD 320. At specified times, medium was aspirated and cells were 
fixed in 4% paraformaldehyde for 15 minutes at room temperature. Paraformaldehyde was 
aspirated and the cells were then washed in PBS thrice, permeabilized with 0.5% Triton 
X-100 followed by PBS wash thrice. Cells were then blocked with 5% bovine serum 
albumin in PBS for 1 h, following which mouse monoclonal anti-γ-H2AX antibody 
(Millipore) was added at a dilution of 1:200 in 1% bovine serum albumin in PBS and 
incubated for 1 h at room temperature. Cells were then washed thrice in PBS before 
incubating in the dark with donkey anti-mouse Alexa Fluor 594 (Invitrogen) at a dilution of 
1:1000 in 1% bovine serum albumin in PBS for 1 h. The secondary antibody solution was 
then aspirated and the cells were washed three times in PBS. Cells were then examined 
using a Leica confocal microscope.
Tumor efficacy
PC3 or SW620 cells (1 × 106 cells in 200uL 1:1 RPMI-1640 and matrigel) were injected s.c. 
into the left flank of 6-8 week-old male Nu/Nu mice to develop xenograft tumors. Ten days 
after inoculation, the mice were randomly distributed into different groups for subsequent 
treatment. Saline, vorinostat, NP vorinostat, was tail vein i.v. injected at an equivalent dose 
of 0.93 mg/kg vorinostat. Quisinostat or NP quisinostat was tail vein i.v. injected at an 
equivalent dose of 1.33 mg/kg quisinostat. Three hours post-injection, the tumors were 
subjected to a dose of 3 Gy with Precision XRAD 320. The mice were covered with a lead 
shield to allow irradiation of the tumor site and minimal irradiation to other organs. Tumor 
volumes were measured every 2 days by measuring two perpendicular diameters with a 
caliper. The tumor volume was calculated with the formula V= 0.5 × a × b2 where a is the 
larger diameter and b is the smaller diameter. The relative change in tumor volume was 
calculated using the relation Vi/Vo, where Vi is the volume on measured day and Vo is the 
initial volume on day 0. Animals were monitored in accordance to the guidelines presented 
in the University of North Carolina Institutional Animal Care and Use Committee approved 
protocol for this study. For statistical analysis, we calculated the area under the growth curve 
(AUC). On the basis of the AUCs, the Wilcoxon rank sum test was performed to compare 
the growth rates between the two groups. The exact one-sided p-value of the Wilcoxon rank 
sum test was calculated. Data were considered statistically significant when the p value was 
less than 0.05.
RESULTS
In this study, we synthesized NP formulations of two HDACIs: established first generation 
HDACI vorinostat and novel second generation HDACI quisinostat. Lipid-polymer NPs 
were prepared using a modified nanoprecipitation method [18]. Vorinostat and quisinostat 
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are hydrophobic molecules, which allowed for NP encapsulation. We investigated two forms 
of PLGA polymers: ester- and carboxyl-terminated PLGA. We also studied PLGA with 
different percentages of lactide and glycolide moieties (e.g. 50:50 and 85:15 PLGA) since 
polymer composition can determine the degradation rate of the lipid-polymer NP carrier, 
which in turn affects the drug release rate [19]. The effects of the investigated parameters on 
NP formation are summarized in Table S1-S2.
We found that NP formulations of vorinostat synthesized with ester-terminated PLGA with 
a lactide and glycolide ratio of 85:15 were more compact in size and monodisperse 
compared with NPs formulated with either ester or acid-terminated 50-50 PLGA (Table S1). 
In general, NPs with sizes below 200 nm preferentially accumulate in tumor tissues via the 
enhanced permeability and retention (EPR) effect [20]. NP quisinostat synthesized with 
either acid or ester-terminated 50:50 PLGA did not form particles with sizes suitable for 
tumor uptake (Table S1). In contrast, NP quisinostat synthesized with 85:15 PLGA possess 
sizes of 125.7±2.4 nm. The end-group functionalization of PLGA also affected particle size 
and polydispersity. We found that NP vorinostat formulated with carboxyl-terminated 50:50 
PLGA possess smaller sizes and was more monodisperse than NP vorinostat synthesized 
with ester-terminated 50:50 PLGA. Furthermore, NP vorinostat synthesized with ester-
terminated 85:15 PLGA was both smaller in size and had higher drug loading than NPs 
formulated with carboxyl-terminated 50:50 PLGA (Table S2).
Therefore, for the following studies, we formulated lipid-polymer NP vorinostat and NP 
quisinostat with 85:15 ester-terminated PLGA (Fig. 1a). The loading attained was 2.2% of 
vorinostat by weight and 2.3% of quisinostat by weight. As shown in Figure 2a, both NP 
vorinostat and NP quisinostat demonstrated consistent spherical morphologies on TEM. 
Dynamic Light Scattering (DLS) analysis showed that NP vorinostat possess sizes of 
72.6±3.6 nm, surface charges (ζ potential) of −38.4±2.6 mV and a polydispersity of 
0.07±0.01. NP quisinostat was found to possess sizes of 125.7±2.4 nm and ζ potential of 
−17.5±3.1 mV. The monodisperse NPs had a polydispersity index of 0.06±0.01.
Next, we characterized the drug release kinetics of vorinostat and quisinostat from the NPs. 
Drug release studies were conducted by dialyzing NPs containing vorinostat or quisinostat 
against 4 L of PBS at pH 7.4 and 37°C to mimic physiological conditions. High-
performance liquid chromatography (HPLC) confirmed the release of intact vorinostat or 
quisinostat from the NPs. Drug delivery carriers formed from PLGA with a higher content 
of lactide to glycolide moieties (e.g. 85:15 PLGA) are less hydrophilic and thus degrade 
slower than NPs engineered with higher glycolic acid content [19]. Thus, we theorized that 
our NP formulations of the HDACIs will have a slow release profile. As shown in Figure 2b, 
NP vorinostat releases its cargo in a controlled fashion over 4 days, with >95% drug release 
thereafter. The release of NP quisinostat also demonstrated slow, controlled drug release 
kinetics with 95% of the drug released from the NP at 4 days (Fig. 2b). These results suggest 
that our designed NPs enable sustained release of HDACIs. Such prolonged drug release can 
cause increased synergistic effects between NP HDACIs and radiotherapy, resulting in 
improved therapeutic efficacy. In the following set of experiments, we evaluated NP 
HDACIs as radiosensitizers in vitro in five tumor cell lines representing three different 
carcinomas: HCT116 (colon cancer), SW620 (colon cancer), SW837 (rectal cancer), PC3 
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(prostate cancer) and DU145 (prostate cancer). We conducted radiosensitization 
experiments using 1 μ M concentration of NP vorinostat, NP quisinostat, vorinostat or 
quisinostat at small molecule equivalent dose with radiotherapy occurring 24 h following 
HDACI treatment. The surviving fractions were determined at each radiotherapy dose level. 
As shown in the clonogenic survival curves depicted in Figure 3, NP vorinostat is more 
effective than small molecule vorinostat in PC3, DU145, HCT116, and SW837 cell lines at 
6 Gy and is nearly as effective as small molecule vorinostat in SW620 cells. We found that 
NP quisinostat is also an effective radiosensitizer in the five cell lines (Fig. 3). Both NP 
vorinostat and NP quisinostat increased the sensitivity of various solid tumor cell lines to 
radiotherapy (Table S3). Specifically, the sensitizer enhancement ratio (SER) of vorinostat 
at 10% survival in DU145 cells is 1.26, whereas the SER of NP vorinostat is 1.27. The SER 
of NP vorinostat at 10% is also greater in HCT116 cells with NP vorinostat at 1.71 and 
vorinostat at 1.48. In SW837 cells, the SER of NP vorinostat at 10% survival is greater at 
1.19 compared to vorinostat at 1.08. In SW620 cells, the SER of quisinostat at 10% survival 
is 1.18 with NP quisinostat at 1.23. Similarly, the SER for NP quisinostat at 10% is greater 
in SW837 cells with NP quisinostat at 1.15 and quisinostat at 1.00. These results suggest 
that NP formulations of HDACIs are potent radiosensitizers.
HDACIs are proposed to sensitize tumor cells to radiotherapy partly through the inhibition 
of DNA damage repair. To compare the relative potency of NP formulation of HDACI and 
their small molecule counterpart to inhibit DNA damage repair, we evaluated the effect of 
NP vorinostat and vorinostat on γH2AX foci, an indicator of DNA DSBs, by 
immunofluorescence microscopy. PC3 tumor cells were treated with 1 μM concentration of 
vorinostat or NP vorinostat at small molecule equivalent dose followed by radiotherapy (2 
Gy). The average number of γH2AX foci per cell was counted and the results are shown in 
Figure 4. Cells treated with vorinostat plus radiotherapy or NP vorinostat plus radiotherapy 
produced a greater number of γH2AX foci compared to cells treated with radiotherapy alone 
(Fig. S1, Fig. 4). In both vorinostat and NP vorinostat-treated cells, radiation-induced 
γH2AX foci were present and the complexes persisted for the duration of the culture (Fig. 
4). The prolongation of γH2AX foci suggests that NP vorinostat has similar inhibitory 
effects as vorinostat against the repair of DNA damage. We observed that treatment with NP 
vorinostat alone had a slight effect on γH2AX foci compared with vorinostat alone. 
Treatment with NP vorinostat also resulted in a higher number of radiotherapy-induced 
γH2AX foci compared to vorinostat. Specifically, a marked increase in γH2AX foci was 
seen in NP vorinostat-treated cells 12 and 24 hours post-radiotherapy compared with cells 
treated with small molecule vorinostat. These results indicate that NP vorinostat is more 
effective than small molecule vorinostat in increasing the inhibition of DNA DSB repair 
post-radiotherapy. Generally, the persistence of DNA damage can also lead to increased 
tumor cell death.
To confirm our in vitro findings that NP HDACIs are effective radiosensitizers, we 
evaluated the therapeutic efficacy of NP vorinostat as a radiosensitizer using a murine 
xenograft model of cancer. Mice bearing PC3 flank xenograft tumors were treated with 
saline, vorinostat or NP vorinostat followed by a single dose of radiotherapy. Tumor 
volumes were measured and tumor growth delay curves were generated (Fig. 5). We 
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observed a significant difference in tumor growth delay between small molecule vorinostat 
and NP formulation of vorinostat with the latter being more effective (Fig. 5a). The 
difference between saline and vorinostat plus radiotherapy does not appear significant (p = 
0.05). When the tumor growth delay curves were compared between mice receiving saline 
and NP vorinostat, the difference in delay was found to be statistically significant (p < 0.01). 
We also investigated the therapeutic efficacy of NP quisinostat as a radiosensitizer in vivo. 
Mice bearing subcutaneous flank xenografts of SW620 cells were administered saline, 
quisinostat only, NP quisinostat only, quisinostat followed by a single dose of radiotherapy 
or NP quisinostat followed by a single dose of radiotherapy (Fig. 5b, Fig. S2). The 
difference between saline and quisinostat plus radiotherapy does not appear significant in 
SW620 cells (p = 0.22) although the trend is consistent with such observation (Fig. 5b). In 
contrast, NP quisinostat plus radiotherapy was found to be more effective than saline or 
radiotherapy only (Fig. 5b). These results indicate that NP formulation of HDACIs markedly 
increases the efficacy of HDACIs as radiosensitizers in colorectal and prostate carcinomas. 
Our in vivo data demonstrate the potential of NP HDACIs in improving chemoradiotherapy.
DISCUSSION
HDACIs represent a class of therapeutics that have considerable potential in targeting 
epigenetic aberrations associated with cancer growth and development [1]. A variety of 
HDACIs are being assessed in both hematological and solid malignancies. However, in the 
clinic, HDACIs as a monotherapy have shown limited success in solid tumor indications. 
Consequently, there has been extensive interest in using HDACIs in combination with other 
anti-cancer agents such as radiotherapy to increase therapeutic efficacy [21]. The limited 
efficacy of some HDACIs is due in part to pharmacologic parameters such low 
bioavailability and short circulating half-lives that prevent prolonged drug exposure. 
Vorinostat, one of the two HDACIs currently approved in the clinic, has a bioavailability of 
43% and a half-life of approximately 2.0 h [22]. As a result of these limitations, novel 
HDACIs such as quisinostat have been designed to be more potent [13]. On the other hand, 
these HDACIs also incur increased toxicity to normal tissues. The present studies, using NP 
formulations of vorinostat and quisinostat, were therefore performed to improve the 
therapeutic efficacy of HDACI-based chemoradiotherapy. To our knowledge, there have 
been no published reports of drug delivery vehicles that improve the therapeutic index of 
HDACIs.
We reported the synthesis of lipid-polymer NPs for the delivery of HDACIs for 
chemoradiotherapy. The optimization of NP HDACIs was investigated since the physical 
characteristics of the NPs can play an important role in the exposure of drug to cells and 
drug half-life in systemic circulation [23]. In this study, we analyzed the effects of different 
PLGA copolymer ratios and found NPs formed from PLGA with increased lactic acid to 
glycolic acid improves HDACI loading and lead to more compact particles. We found that 
NP HDACIs formulated with 85:15 ester-terminated PLGA are monodisperse particles with 
sizes approximately 72.6 nm for NP vorinostat and 125.6 nm for NP quisinostat. We 
demonstrated that both NP vorinostat and NP quisinostat release their cargo in a slow and 
controlled fashion, with approximately 50% drug release after 24 hours and >95% of drug 
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release after 4 days. Such slow drug release can increase the drug exposure time, which can 
lead to increased synergistic activity between the HDACIs and radiotherapy in tumor cells.
Our study compared the therapeutic ratio of NP HDACIs as radiosensitizers to that of small 
molecule HDACIs. We demonstrated that NP vorinostat and NP quisinostat were effective 
radiosensitizers in vitro in colorectal and prostate carcinomas. Previous investigations have 
demonstrated that at sites of DNA DSBs, the histone H2AX becomes phosphorylated (γ-
H2AX), forming complexes indicating DNA damage [11]. To evaluate the involvement of 
DNA repair in NP vorinostat-mediated radiosensitization, we tested whether NP vorinostat 
causes a prolongation of γ-H2AX foci, which would suggest a decrease in the rate of repair 
of radiotherapy-induced DNA damage. Our results showed that the number of γ-H2AX foci 
is higher in tumor cells treated with NP vorinostat plus radiotherapy compared with cells 
treated with vorinostat plus radiotherapy. This effect is evident at times up to 24 hours 
following irradiation. Thus, the increased number of γ-H2AX foci in NP vorinostat-treated 
cells may be an indicator that NP vorinostat is a more effective inhibitor of the DSB repair 
pathway than small molecule vorinostat. The ability of NP HDACIs to prolong DNA 
damage repair inhibition can lead to increased cell death.
We also demonstrated that at equivalent doses of small molecule HDACIs, NP HDACIs are 
more effective than their small molecule counterparts in chemoradiotherapy in vivo. NP 
vorinostat was capable of marked tumor growth inhibition in a synergistic manner for over 
60 days after administration of a single irradiation dose of 3 Gy. We also showed that NP 
formulation of quisinostat improved its therapeutic efficacy. These results confirmed our 
hypothesis that NP formulations of HDACIs can significantly improve chemoradiotherapy. 
NP therapeutics offer several advantages in chemoradiotherapy including controlled drug 
release and unique biodistribution. Only the effects of controlled drug release were observed 
in vitro. NP HDACIs were found to be more effective than their small molecule counterparts 
in some cell lines. In other cell lines, the SERs of small molecule HDACIs at 10% survival 
were higher than the SERs of their NP counterparts. This effect was observed with 
vorinostat and NP vorinostat in PC3 cells. However, the in vivo tumor growth delay curves 
demonstrated that NP vorinostat lead to a significantly longer tumor growth delay compared 
with vorinostat in PC3 cells. In the in vivo setting, it is likely then that the significant 
differences in the therapeutic efficacy between small molecule HDACIs and NP HDACIs 
are due to the unique biodistribution of the NP therapeutics. Presumably, NP HDACIs are 
able to accumulate in tumors more than small molecule HDACIs and release their cargo in a 
slow and controlled fashion. This may allow the NPs to exert a greater therapeutic effect, 
leading to a synergistic interaction between the NP HDACIs and radiotherapy.
CONCLUSIONS
In summary, we have synthesized novel NP formulations of HDACIs vorinostat and 
quisinostat. The NP HDACIs are compact in size and release drug in a slow and controlled 
fashion. NP HDACIs were found to prolong DNA DSB repair in tumor cells. NP HDACIs 
were also evaluated in vitro and in vivo in chemoradiotherapy using murine models of 
colorectal and prostate cancer. NP vorinostat and NP quisinostat demonstrated higher 
therapeutic efficacy than small molecule HDACIs. Our work demonstrates that NP 
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formulations of HDACIs are promising cancer therapeutics with the potential to 
significantly improve chemoradiotherapy.
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(A) Schematic of NP formulations of HDACIs. (B) NP therapeutics preferentially 
accumulates in tumors via the EPR effect allowing for tumor tissue to receive both the 
radiosensitizer and radiotherapy.
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Characterization of NP HDACIs. (A) TEM images of NP vorinostat and NP quisinostat 
depicting a monodisperse population of particles with a size distribution of 72.6 ± 3.63 and 
125.7 ± 2.43 respectively. (B) Drug-release curves of NP vorinostat and NP quisinostat. NP 
HDACIs releases HDACI in a first-order release kinetics. NP HDACIs were incubated in 
phosphate buffered saline at 37°C.
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Efficacy of NP vorinostat and NP quisinostat as radiosensitizers in PC3, DU145, HCT116, 
SW620, and SW837 cell lines in vitro. Cells were treated with saline, vorinostat, quisinostat, 
NP vorinostat or NP quisinostat. The cells were then irradiated at different doses (2 Gy, 4 
Gy, 6 Gy and 8 Gy). Surviving fractions of the cells were calculated at each radiotherapy 
dose. Error bars correspond to the standard error of the mean (n=3).
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Influence of vorinostat and NP vorinostat on radiation-induced γ-H2AX foci. PC3 cells were 
grown in a 24-well plate and then treated with vorinostat or NP vorinostat at 1 μM small 
molecule equivalent for 24 h, washed thrice, irradiated (2 Gy), and fixed at the specified 
times for immunocytochemical analysis of nuclear γ-H2AX foci. (A) Micrographs obtained 
from cells exposed to vorinostat or NP vorinostat. (B) Quantitative analysis of foci present 
in the cells following treatments.
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Efficacy of NP HDACIs as radiosensitizers in chemoradiotherapy for solid tumor cell lines 
in vivo. Mice bearing flank tumor xenografts were administered (intravenous) with saline, 
vorinostat, NP vorinostat, quisinostat or NP quisinostat followed by radiotherapy. Tumors 
were irradiated to a total dose of 3 Gy at 3 h after chemotherapy injection. Changes in tumor 
volume were measured and the tumor growth delay curves for mice bearing PC3 (A) and 
SW620 (B) tumors were generated.
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